Last updated: October 10, 2026
Propulsid, the brand name for cisapride, was a high-revenue gastrointestinal drug that lost its U.S. market after regulators linked it to QT prolongation, torsades de pointes, and sudden death. The FDA-approved product was withdrawn from ordinary U.S. distribution in 2000. Its commercial trajectory followed a sharp pattern: rapid uptake as a prokinetic and gastroesophageal reflux treatment, blockbuster-level sales before major safety restrictions, then an abrupt revenue collapse after withdrawal. Propulsid has no current U.S. commercial market, Orange Book exclusivity, or meaningful generic-entry opportunity.
What was Propulsid and how did it generate revenue?
Propulsid was cisapride, a gastrointestinal prokinetic agent developed and marketed by Janssen Pharmaceutica, a Johnson & Johnson company. It increased gastrointestinal motility by enhancing acetylcholine release in the enteric nervous system. The product was marketed for adult patients with nocturnal heartburn associated with gastroesophageal reflux disease and for certain motility disorders.
The commercial opportunity was broad because Propulsid addressed symptoms associated with reflux and delayed gastric emptying before proton-pump inhibitors became dominant. Its principal historical competitors included:
- Metoclopramide, marketed as Reglan
- H2-receptor antagonists such as ranitidine and famotidine
- Proton-pump inhibitors such as omeprazole, lansoprazole, and pantoprazole
- Domperidone in markets outside the United States
- Surgical and non-drug treatment for severe reflux and motility disorders
Propulsid was attractive commercially because it could be prescribed across gastroesophageal reflux and motility-related indications. Its use also expanded beyond the narrow FDA-approved population, including pediatric and infant reflux treatment. That off-label use increased exposure to the product but also increased safety and liability risk.
How did Propulsid sales change before and after withdrawal?
Propulsid reached estimated annual global sales of more than $1 billion near its commercial peak, according to contemporary company and press reporting. Johnson & Johnson did not consistently disclose Propulsid revenue as a separate line item in its consolidated filings, so exact annual brand sales depend on external estimates and market reporting. The financial trajectory can be summarized as follows:
| Period |
Commercial position |
Financial effect |
| Early to mid-1990s |
U.S. launch and rapid adoption as a prokinetic and reflux product |
Strong prescription growth |
| 1995-1998 |
Safety warnings and label restrictions began to affect prescribing |
Growth moderated; monitoring and risk controls increased |
| 1998-1999 |
Product remained a major global seller despite safety concerns |
Estimated blockbuster-level revenue, generally reported above $1 billion annually |
| 2000 |
Janssen withdrew Propulsid from ordinary U.S. distribution |
U.S. revenue fell sharply |
| 2001 onward |
Limited-access use and foreign-market withdrawals reduced exposure |
No meaningful U.S. commercial revenue |
| Current period |
No ordinary U.S. commercial product |
No material current sales or market share |
The withdrawal eliminated a substantial revenue stream for Johnson & Johnson. The company could absorb the impact because its portfolio included pharmaceuticals, medical devices, consumer products, and other high-value brands. The financial effect was nevertheless material because Propulsid had been one of the company’s larger prescription products.
When did Propulsid lose U.S. market exclusivity?
Propulsid lost practical commercial exclusivity when Janssen removed it from ordinary U.S. distribution in 2000. Regulatory withdrawal, rather than generic competition, ended the U.S. business.
The product’s underlying patent protection and any remaining regulatory exclusivity became commercially secondary after the safety-driven withdrawal. A generic company could not create a viable U.S. market merely by obtaining approval for cisapride if the reference product was no longer broadly marketed and the FDA had restricted access because of serious cardiac risk.
The product therefore illustrates the difference between legal exclusivity and economic exclusivity. Even if historical patents or regulatory rights remained relevant for a period, safety restrictions destroyed the commercial value of those rights.
What FDA action ended the Propulsid business?
The FDA and Janssen identified serious cardiac adverse events associated with cisapride, particularly QT prolongation and ventricular arrhythmias. The risk increased in patients with certain cardiac conditions, electrolyte abnormalities, hepatic impairment, or concomitant use of drugs that inhibited CYP3A4 or otherwise affected cardiac repolarization.
The FDA required progressively stronger risk controls, including prescribing restrictions and warnings. In January 2000, Janssen announced the voluntary withdrawal of Propulsid from the U.S. market. Ordinary commercial distribution ended on July 14, 2000, although the drug remained available for selected patients through a limited-access program under FDA oversight [1].
The regulatory sequence was commercially damaging because each warning reduced the addressable patient population, increased physician reluctance, and raised the cost of compliance. The final withdrawal converted a high-volume product into a tightly controlled medicine with little commercial value.
Key FDA safety drivers
The principal safety factors were:
- QT interval prolongation
- Torsades de pointes
- Ventricular tachycardia and ventricular fibrillation
- Sudden death
- Drug-drug interactions involving CYP3A4 inhibitors
- Higher risk among patients with cardiac, hepatic, or electrolyte abnormalities
The risk-benefit profile deteriorated as alternative reflux therapies became more effective and widely accepted. Proton-pump inhibitors provided a commercially competitive option without the same recognized arrhythmia liability.
What was Propulsid’s competitive position against proton-pump inhibitors?
Propulsid competed in a market that shifted toward acid suppression. Proton-pump inhibitors became the preferred treatment for many patients with erosive esophagitis and chronic reflux because they delivered stronger and more consistent acid control.
| Product class |
Representative drugs |
Competitive effect on Propulsid |
| Prokinetics |
Cisapride, metoclopramide |
Direct competition for motility-related symptoms |
| H2 blockers |
Ranitidine, famotidine |
Lower-cost treatment for reflux |
| Proton-pump inhibitors |
Omeprazole, lansoprazole, pantoprazole |
Stronger clinical and commercial alternative for acid-mediated disease |
| Dopamine antagonists and other agents |
Domperidone, selected regional products |
Alternative prokinetic treatment outside the U.S. |
Propulsid had a differentiated mechanism, but that advantage was outweighed by cardiac risk. The product also faced a narrower commercial future as physicians moved toward therapies with better-established safety and reimbursement support.
What litigation affected Propulsid’s financial trajectory?
Propulsid generated extensive product-liability litigation involving arrhythmia, sudden death, and other alleged cardiac injuries. Plaintiffs generally alleged that Janssen and related entities knew or should have known about the cardiac risk and failed to provide adequate warnings or restrict use quickly enough.
Reported litigation consequences included:
- Large numbers of individual personal-injury claims
- Multidistrict and coordinated state-court proceedings
- Settlements involving thousands of claimants
- Legal-defense expenses
- Product-liability reserves
- Reputational and physician-confidence damage
In 2004, Janssen was reported to have agreed to a settlement of approximately $90 million involving thousands of Propulsid claims, without admitting liability. The settlement did not end every potential claim, and litigation continued in various forms. Johnson & Johnson’s annual reports discussed product-liability exposure and litigation reserves across multiple products, making it difficult to isolate the total lifetime financial cost of Propulsid from public consolidated disclosures [2].
The economic burden extended beyond settlement payments. Withdrawal reduced future sales while the company continued to bear costs related to legal defense, claims administration, regulatory compliance, and patient communications.
What was the financial impact of the Propulsid withdrawal on Johnson & Johnson?
The primary financial impact was the loss of a blockbuster pharmaceutical franchise. The withdrawal affected:
- Prescription revenue from the United States and other markets.
- Gross profit associated with a mature, high-volume product.
- Brand value and physician confidence in the Janssen gastrointestinal portfolio.
- Legal and regulatory expense.
- Reserve requirements for product-liability claims.
The withdrawal did not threaten Johnson & Johnson’s overall solvency or pharmaceutical platform. Its diversified operations and broader prescription portfolio reduced concentration risk. The event still demonstrated that a single safety signal can destroy the value of a high-revenue medicine after significant development and commercialization investment.
A direct year-by-year Propulsid revenue series is not available from Johnson & Johnson’s consolidated public reporting. External estimates place peak global sales above $1 billion, but reported figures differ because analysts used different geographic periods and definitions of brand revenue. The reliable financial conclusion is the direction of movement: substantial pre-withdrawal revenue followed by a near-total collapse in U.S. sales after 2000.
What is the current Orange Book status of Propulsid?
Propulsid has no meaningful current U.S. Orange Book commercial position. The product was withdrawn for safety reasons, not because of ordinary patent expiration or generic substitution. No active U.S. commercial market supports a current Orange Book-based launch strategy for cisapride.
A historical cisapride generic would also face regulatory and commercial barriers:
- The reference product is not broadly marketed.
- FDA restrictions limit ordinary access.
- Cardiac safety concerns complicate labeling and risk management.
- Physicians have safer and more established alternatives.
- Payers have little reason to favor cisapride.
- Product-liability exposure would be disproportionate to likely demand.
There is no current Paragraph IV challenge of commercial importance associated with Propulsid. Any historical patent challenge would have lost strategic value once the branded product was withdrawn.
Are formulation or method-of-use patents commercially relevant?
Historical intellectual-property protection likely covered cisapride compounds, pharmaceutical compositions, dosage forms, and therapeutic uses. Those rights are no longer meaningful commercial barriers in the United States.
The key issue is not whether a formulation or method-of-use patent could technically be identified. The issue is whether a patent-protected cisapride product could obtain and sustain a viable market. The FDA’s safety history would make a new formulation difficult to commercialize unless it materially changed systemic exposure or cardiac risk. Even then, clinical development, risk-management requirements, and physician adoption would create substantial barriers.
A reformulated product would likely require new clinical evidence rather than relying solely on historical approval. A manufacturer would also need to establish that its product avoided the arrhythmia risks that caused the original withdrawal.
What manufacturing and regulatory barriers remain for cisapride?
Manufacturing cisapride as an active pharmaceutical ingredient is technically feasible, but commercial manufacture for the U.S. market faces higher barriers than ordinary generic production.
Important barriers include:
- Demonstrating acceptable impurity and stability profiles
- Establishing consistent dosage-form performance
- Addressing cardiac electrophysiology risks
- Meeting FDA requirements for restricted distribution or monitoring
- Obtaining physician and payer acceptance
- Managing product-liability exposure
- Finding a commercially adequate patient population
The manufacturing process itself is less important than the regulatory and clinical burden. A low-cost active ingredient would not solve the product’s central problem: the risk-benefit profile is unfavorable against newer gastrointestinal therapies.
How strong is the Propulsid patent estate today?
The current commercial strength of the Propulsid patent estate is effectively zero in the United States. Historical patents may have provided protection during the product’s commercial life, but patent expiry and safety withdrawal eliminated their strategic value.
The estate has no material ability to:
- Delay a modern generic launch
- Support a licensing premium
- Protect a growing market
- Generate meaningful royalty revenue
- Prevent substitution by other gastrointestinal therapies
The relevant asset today is historical regulatory and litigation information, not enforceable commercial exclusivity.
What generic launch scenarios existed for Propulsid?
Three generic-launch scenarios were theoretically possible:
Immediate generic substitution before withdrawal
This scenario would have required FDA approval while Propulsid remained commercially available. Safety warnings and restrictions reduced the attractiveness of this path.
Limited-access generic supply after withdrawal
A manufacturer could theoretically supply cisapride to eligible patients under a restricted program. The addressable market would be small, and distribution controls would reduce margins.
Reformulated or risk-reduced cisapride product
A new formulation could seek approval if it materially improved safety. This would require substantial clinical and regulatory investment, with no assurance of commercial acceptance.
None of these scenarios provides a strong current business case. The product’s market failure was caused by safety and therapeutic substitution, not by supply constraints.
How does Propulsid compare with other withdrawn drugs?
Propulsid differs from drugs withdrawn after modest sales because it had already achieved blockbuster penetration. Its withdrawal therefore produced a larger absolute revenue loss and broader litigation exposure.
| Drug |
Primary withdrawal issue |
Commercial pattern |
| Propulsid, cisapride |
Cardiac arrhythmia and QT prolongation |
Blockbuster sales followed by rapid withdrawal |
| Vioxx, rofecoxib |
Cardiovascular risk |
Major revenue loss and extensive litigation |
| Lotronex, alosetron |
Ischemic colitis and severe constipation |
Withdrawal followed by restricted reintroduction |
| Redux, dexfenfluramine |
Valvular heart disease and pulmonary hypertension |
Rapid market exit after safety findings |
Propulsid had no comparable commercial reintroduction in the United States. Its indication became less necessary as alternative reflux drugs improved.
Key takeaways
- Propulsid was cisapride, a Janssen gastrointestinal prokinetic.
- Peak global sales were widely estimated at more than $1 billion annually.
- FDA safety concerns centered on QT prolongation, torsades de pointes, and sudden death.
- Janssen withdrew Propulsid from ordinary U.S. distribution in 2000.
- The financial decline was caused by regulatory withdrawal and liability exposure, not ordinary generic erosion.
- Proton-pump inhibitors weakened the product’s competitive position before withdrawal.
- Historical patents and formulation rights have no material current U.S. commercial value.
- There is no meaningful current Orange Book, Paragraph IV, or generic-launch opportunity.
- Product-liability settlements and legal costs added to the lost-revenue impact.
- Any modern cisapride strategy would face severe clinical, regulatory, commercial, and liability barriers.
FAQs about Propulsid market dynamics and financial history
Why was Propulsid withdrawn from the market?
Propulsid was withdrawn because cisapride was associated with QT prolongation and life-threatening ventricular arrhythmias, particularly when used with certain medicines or in high-risk patients.
Did generic competition cause Propulsid sales to collapse?
No. The primary cause was regulatory withdrawal and safety restrictions. Generic competition was not the main driver of the U.S. revenue collapse.
Was Propulsid a billion-dollar drug?
Contemporary reports generally estimated global peak sales above $1 billion annually. Johnson & Johnson’s public filings did not always disclose a separate, audited Propulsid revenue line.
Can cisapride still be prescribed in the United States?
Cisapride was made available to selected patients through a restricted FDA access mechanism after commercial withdrawal. It is not an ordinary broadly marketed U.S. prescription product.
Does Propulsid still have licensing value?
Its historical patents and brand rights have little current licensing value. A new commercial opportunity would require overcoming the safety concerns that ended the original product’s market.
References
-
U.S. Food and Drug Administration. (2000). FDA announces withdrawal of Propulsid from the U.S. market. FDA Drug Safety Communications.
-
Johnson & Johnson. (1999-2001). Annual reports. New Brunswick, NJ: Johnson & Johnson.
-
U.S. Food and Drug Administration. (2000). Cisapride-containing products: revised labeling and limited-access program information. FDA.
-
U.S. General Accounting Office. (2000). Prescription drugs: FDA guidance and postmarketing safety oversight. Washington, DC: U.S. Government Printing Office.
-
Janssen Pharmaceutica Products, L.P. (2000). Propulsid prescribing information and safety communications. Titusville, NJ: Janssen Pharmaceutica.
